BioSpace News Archive

Evaxion Biotech A/S, a clinical-stage AI-immunology company developing immunotherapies to improve the lives of patients with cancer and infectious diseases, announced the publication of an article in Nature Communications showing how deep data on immune complex stability could optimize immunotherapy in cancer.

The European Investment Bank (EIB) has signed a €20 million loan agreement with Evaxion, supported by the Infectious Diseases Finance Facility window under the EU’s InnovFin – EU finance for innovators program, backed by the EU’s research and innovation program Horizon 2020

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the three months ended September 30, 2020, on Wednesday, December 16, 2020,

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors.

SoniVie, an Israeli company developing a novel proprietary Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, today announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the TIVUS System

Intec Pharma Ltd. announces it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill platform for an undisclosed research program.

ZielBio, Inc., an early-stage biotechnology company discovering new treatments for cancer and other serious diseases through its innovative drug discovery platform, has appointed industry veteran Dieter Weinand as the company’s new Executive Chair.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the progression of REDWOOD-HCM following the conduct of an interim analysis of data from Cohort 1. REDWOOD-HCM ( R andomized E valuation of D osing W ith CK-274 in O bstructive O utflow D isease in HCM ) is an ongoing Phase 2 clinical trial of CK-3773274 (CK-274), a next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic car

PepGen’s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round

Protech Home Medical Corp. a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, announced that Dr. Kevin A. Carter has joined the board of directors of the Company as an independent director.